CN102917706A - 含有克拉夫定及阿德福韦酯的用于治疗慢性乙型肝炎的组合物 - Google Patents

含有克拉夫定及阿德福韦酯的用于治疗慢性乙型肝炎的组合物 Download PDF

Info

Publication number
CN102917706A
CN102917706A CN201180024843XA CN201180024843A CN102917706A CN 102917706 A CN102917706 A CN 102917706A CN 201180024843X A CN201180024843X A CN 201180024843XA CN 201180024843 A CN201180024843 A CN 201180024843A CN 102917706 A CN102917706 A CN 102917706A
Authority
CN
China
Prior art keywords
clevudine
virus
adefovir ester
adefovir
hepatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201180024843XA
Other languages
English (en)
Chinese (zh)
Inventor
李圣求
李荣春
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bukwang Pharmaceutical Co Ltd
Gilead Sciences Inc
Original Assignee
Triangle Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020100046543A external-priority patent/KR20100127180A/ko
Application filed by Triangle Pharmaceuticals Inc filed Critical Triangle Pharmaceuticals Inc
Publication of CN102917706A publication Critical patent/CN102917706A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201180024843XA 2010-05-18 2011-04-18 含有克拉夫定及阿德福韦酯的用于治疗慢性乙型肝炎的组合物 Pending CN102917706A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020100046543A KR20100127180A (ko) 2009-05-25 2010-05-18 클레부딘 및 아데포비어 디피복실을 함유하는 만성 ｂ형 간염 치료용 조성물
KR10-2010-0046543 2010-05-18
PCT/KR2011/002747 WO2011145808A2 (ko) 2010-05-18 2011-04-18 클레부딘 및 아데포비어 디피복실을 함유하는 만성 ｂ형 간염 치료용 조성물

Publications (1)

Publication Number Publication Date
CN102917706A true CN102917706A (zh) 2013-02-06

Family

ID=44993236

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180024843XA Pending CN102917706A (zh) 2010-05-18 2011-04-18 含有克拉夫定及阿德福韦酯的用于治疗慢性乙型肝炎的组合物

Country Status (3)

Country Link
CN (1) CN102917706A (ko)
SG (1) SG185545A1 (ko)
WO (1) WO2011145808A2 (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116327793A (zh) * 2021-06-07 2023-06-27 天津济坤医药科技有限公司 克拉夫定在制备治疗特发性肺纤维化的药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030158150A1 (en) * 1998-11-02 2003-08-21 Triangle Pharmaceuticals, Inc. Combination therapy to treat hepatitis B virus

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2381266T3 (es) * 2002-07-15 2012-05-24 Gilead Sciences, Inc. Terapias de combinación de L-FMAU para el tratamiento de la infección por el virus de la hepatitis B
US20080261913A1 (en) * 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030158150A1 (en) * 1998-11-02 2003-08-21 Triangle Pharmaceuticals, Inc. Combination therapy to treat hepatitis B virus

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BRUNELLE ET AL: "Susceptibility to Antivirals of a Human HBV Strain with Mutations Conferring Resistance to Both Lamivudine and Adefovir", 《HEPATOLOGY》 *
IM, HYEONG JUN: "Managment of Antiviral-Resistant Chronic Hepatitis B Virus Infection", 《JOURNAL OF KOREAN SOCIETY OF GASTROENTEROLOGY》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116327793A (zh) * 2021-06-07 2023-06-27 天津济坤医药科技有限公司 克拉夫定在制备治疗特发性肺纤维化的药物中的应用
CN116327793B (zh) * 2021-06-07 2024-02-23 天津济坤医药科技有限公司 克拉夫定在制备治疗特发性肺纤维化的药物中的应用

Also Published As

Publication number Publication date
WO2011145808A3 (ko) 2012-02-23
SG185545A1 (en) 2012-12-28
WO2011145808A2 (ko) 2011-11-24

Similar Documents

Publication Publication Date Title
Liang et al. A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir
JP2022184924A (ja) 免疫応答を増強するためのメッセンジャーリボ核酸及びその使用方法
JP2023512656A (ja) ＳＡＲＳ ＣｏＶ－２感染を治療するための方法
US7928086B2 (en) β-L-2′-deoxynucleosides for the treatment of resistant HBV strains and combination therapies
TW202104210A (zh) Hiv蛋白酶抑制劑
JP2001500471A (ja) プロテアーゼインヒビターの生物学的及び抗ウイルス活性を改善する方法
TWI820984B (zh) 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型
WO2003050129A1 (en) Use of phosphonate nucleotide analogue for treating hepatitis b virus infections
WO2003080078A1 (en) Treatment of pre-core hepatitis b virus mutant infections
WO2007143934A1 (fr) Composition pharmaceutique destinée à la prophylaxie et au traitement d'une infection par le vih et son utilisation
JP2020203947A (ja) Ｎｓ５ａ、ｎｓ５ｂまたはｎｓ３阻害剤を使用する、ｂ型肝炎ウイルス感染症を処置するための方法
CN104066324A (zh) 治疗痛风急性发作的方法
CN100497279C (zh) 一类对映桉烷醇类倍半萜抑制乙肝病毒的医药用途
CN106902346A (zh) 药物组合物及其制药用途
PT1382343E (pt) Terapia de combinação para tratamento do vírus da hepatite b
CN102917706A (zh) 含有克拉夫定及阿德福韦酯的用于治疗慢性乙型肝炎的组合物
CN101287744A (zh) 抗病毒化合物
CN112121044A (zh) 氨来占诺用于制备抗肝炎病毒药物的用途
CN114796233A (zh) 积雪草酸在制备乙型肝炎治疗药物中的用途
CN111265502B (zh) 香紫苏醇和香紫苏内酯在抗丝状病毒感染中的应用
JP4806187B2 (ja) Ｂ型肝炎ウイルスの治療のためのｌ−ｆｍａｕとの併用療法
US20210347813A1 (en) Compounds with hiv maturation inhibitory activity
EP0255420A2 (en) Antiviral agent for inhibiting growth of virus of acquired immune deficiency syndrome (AIDS)
KR20100127180A (ko) 클레부딘 및 아데포비어 디피복실을 함유하는 만성 ｂ형 간염 치료용 조성물
JP2021520407A (ja) Ｂ型肝炎ウィルス（ｈｂｖ）感染を処置する方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130206